A highly D3R-selective and efficacious partial agonist (S)-ABS01-113 compared to its D3R-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorder.  Galaj E, Bi GH, Klein B, Hempel B, Shaik AB, Gogarnoiu E...

Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province. Sadek J, Saunders J.  BMC Psychiatry. 2022 Jul 30;22(1):516. do...

The influence of poly-drug use patterns on the association between opioid agonist treatment engagement and injecting initiation assistance.  Meyers-Pantele SA, Mittal ML, Jain S, Sun S, Rammohan I, Fairbairn N, Milloy MJ, DeBeck K, Hayashi K...

The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review.  Jordan CG, Kennalley AL, Roberts AL, Nemes KM, Dolma T, Piper BJ.  Pharmacy (Basel). 2022 Apr 19;10(3):48. doi: 10.3390/pharmacy10030048...

What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings.  Hooker SA, Sherman MD, Lonergan-Cullum M, Nissly T, Levy R.  J Subst Abuse Treat. 2022 May 20:108804. doi: 10.1016...

What factors influence retention in buprenorphine and methadone treatment? Medication treatments for opioid use disorder are effective lifesaving therapies, and studies suggest that longer treatment durations result in better patient outcomes (e....